Podstawowe statystyki
| LEI | 8MCWUBXQ0WE04KMXBX50 |
| CIK | 1022079 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Quest Diagnostics Incorporated
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| May 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 20, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 6, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 8, 2026 |
Exhibit 4.2 QUEST DIAGNOSTICS INCORPORATED, as Issuer and THE BANK OF NEW YORK MELLON, as Trustee Twenty-Fourth Supplemental Indenture Dated as of May 6, 2026 TABLE OF CONTENTS Page Article I. DEFINITIONS 3 SECTION 1.1. Certain Terms Defined in the Indenture 3 SECTION 1.2. Definitions 3 SECTION 1.3. Other Definitions 6 Article II. FORM AND TERMS OF THE NOTES 6 SECTION 2.1. Form and Dating 6 SECTIO |
|
| May 1, 2026 |
Quest Diagnostics Prices $500 Million of Senior Notes Exhibit 99.1 Quest Diagnostics Prices $500 Million of Senior Notes SECAUCUS, NJ – April 27, 2026 /PRNewswire/ –Quest Diagnostics Incorporated (NYSE: DGX) (the “Company”), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under Quest Diagnostics' shelf registratio |
|
| May 1, 2026 |
Exhibit 1.1 Execution Version QUEST DIAGNOSTICS INCORPORATED (a Delaware corporation) $500,000,000 5.000% Senior Notes due 2036 UNDERWRITING AGREEMENT Dated: April 27, 2026 Table of Contents Page SECTION 1. Representations and Warranties 2 (a) Representations and Warranties by the Company 2 (b) Officer’s Certificates 13 SECTION 2. Sale and Delivery to Underwriters; Closing 13 (a) Notes 13 (b) Publ |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 27, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 28, 2026 |
Calculation of Filing Fee Tables S-3 QUEST DIAGNOSTICS INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt 5. |
|
| April 28, 2026 |
$500,000,000 Quest Diagnostics Incorporated $500,000,000 5.000% senior notes due 2036 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-288188 PROSPECTUS SUPPLEMENT (To prospectus dated June 20, 2025) $500,000,000 Quest Diagnostics Incorporated $500,000,000 5.000% senior notes due 2036 We are offering $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “notes”). The notes will mature on June 30, 2036. We will pay interest on the note |
|
| April 27, 2026 |
Subject to Completion Preliminary Prospectus Supplement, dated April 27, 2026 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| April 27, 2026 |
Free Writing Prospectus Filed pursuant to Rule 433 April 27, 2026 Registration Statement No. |
|
| April 22, 2026 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of April 22, 2026, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| April 22, 2026 |
exhibit101-2026equityawa Equity Award Agreement Page | 1 Quest Diagnostics Incorporated 2026 Equity Award Agreement This Equity Award Agreement (the “Agreement”) dated as of #GrantDate# (the “Grant Date”) between Quest Diagnostics Incorporated, 500 Plaza Drive, Secaucus, NJ 07094 (the “Company”) and the employee to whom the awards described herein are made (the “Employee”) is subject in all respects to the Company’s Amended and Restated Employee Long-Term Incentive Plan (the “Plan”). |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 21, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 21, 2026 |
Exhibit 99.1 Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 •First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth •First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025 •Full year 2026 reported diluted EP |
|
| April 6, 2026 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2026 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 9, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| March 12, 2026 |
Exhibit 99.1 Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors SECAUCUS, N.J., March 12, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned bus |
|
| February 26, 2026 |
dgx12312025ex9916 EXECUTION VERSION AMENDMENT NO. 12 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 12 to Sixth Amended and Restated Credit and Security Agreement (this “Amendment”), effective as of November 20, 2025 (the “Effective Date”), is entered into by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors and |
|
| February 26, 2026 |
dgx12312025ex107 Exhibit 10.7 |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| February 26, 2026 |
dgx12312025ex101 1 Amended and Restated Employee Stock Purchase Plan (As approved by the stockholders on May 4, 2006 and as amended effective as of November 6, 2025) The purpose of the Employee Stock Purchase Plan (the “Program”) of Quest Diagnostics Incorporated (the “Corporation”) is to provide to employees an ongoing opportunity to purchase shares of Common Stock of the Corporation, par value $0. |
|
| February 26, 2026 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of February 26, 2026, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| February 26, 2026 |
dgx12312025ex1013 Exhibit 10.13 AMENDMENT NO. 2 TO THE QUEST DIAGNOSTICS PROFIT SHARING PLAN (as amended and restated effective September 14, 2023) The Quest Diagnostics profit sharing Plan, as presently maintained under an amendment and restatement effective as of September 14, 2023 (the "Plan"), is hereby amended, effective as of January 1, 2025 (unless a different effective date is indicated), |
|
| February 26, 2026 |
Exhibit 21.1 Quest Diagnostics Incorporated (DE) (Incorporated on December 12, 1990 in Delaware; EIN: 16-1387862) Subsidiaries, Joint Ventures and Affiliates Company Registered Alternate name 100% Quest Diagnostics Holdings Incorporated (DE) 100% Quest Diagnostics International Holdings Limited (UK) 100% Quest Diagnostics Holdings Ltd. (UK) 100% ExamOne Canada, Inc. (New Brunswick, Canada) 99.9% Q |
|
| February 10, 2026 |
Exhibit 99.1 Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share •Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 •Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 •Full year re |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 10, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 10, 2026 |
Exhibit 99.2 Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter; Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization SECAUCUS, N.J., Feb. 10, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| January 12, 2026 |
PRESENTATION DATED JANUARY 12, 2026 Exhibit 99.1 Driving Sustainable Growth, Delivering Long-term Value Jim Davis Chairman, CEO, and President J.P. Morgan Healthcare Conference January 12, 2026 Quest Diagnostics Safe harbor disclosure The statements in this presentation that are not historical facts may be forward-looking statements. Readers and listeners are cautioned not to place undue reliance on forward-looking statements, which |
|
| October 21, 2025 |
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 •Third quarter revenues of $2.82 billion, up 13.1% from 2024 •Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024 •Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 •Full y |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 21, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| October 21, 2025 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of October 21, 2025, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| September 26, 2025 |
144 0001222679 XXXXXXXX LIVE 0001022079 QUEST DIAGNOSTICS INC 001-12215 500 PLAZA DRIVE SECAUCUS NJ 07094 9735202700 PREVOZNIK MICHAEL E Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 227 42706. |
|
| September 24, 2025 |
144 0001222679 XXXXXXXX LIVE 0001022079 QUEST DIAGNOSTICS INC 001-12215 500 PLAZA DRIVE SECAUCUS NJ 07094 9735202700 PREVOZNIK MICHAEL E Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 175 32729. |
|
| September 23, 2025 |
144 0001222679 XXXXXXXX LIVE 0001022079 QUEST DIAGNOSTICS INC 001-12215 500 PLAZA DRIVE SECAUCUS NJ 07094 9735202700 PREVOZNIK MICHAEL E Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 28288 5293313. |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| July 23, 2025 |
dgx06302025ex992 EXECUTION VERSION [[6690694]] AMENDMENT AND RESTATEMENT AGREEMENT, dated as of April 30, 2025 (this “Amendment”), relating to the THIRD AMENDED AND RESTATED CREDIT AGREEMENT dated as of November 23, 2021 (as amended, amended and restated, supplemented or otherwise modified prior to the date hereof, the “Existing Credit Agreement”), among QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation (the “Borrower”), the LENDERS from time to time party thereto, JPMORGAN CHASE BANK, N. |
|
| July 23, 2025 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of July 23, 2025, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| July 23, 2025 |
dgx06302025ex991 EXECUTION VERSION Quest Amendment No. 11 to 6th A&R CSA 281711255.v2 AMENDMENT NO. 11 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 11 to Sixth Amended and Restated Credit and Security Agreement (this “Amendment”) is entered into as of April 30, 2025 (the “Effective Date”), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporatio |
|
| July 23, 2025 |
EXHIBIT 99.3 [[6671007]] FOURTH AMENDED AND RESTATED CREDIT AGREEMENT Dated as of April 30, 2025 among QUEST DIAGNOSTICS INCORPORATED, as Borrower, THE LENDERS IDENTIFIED HEREIN, JPMORGAN CHASE BANK, N.A., as Administrative Agent, and MORGAN STANLEY SENIOR FUNDING, INC., as Syndication Agent JPMORGAN CHASE BANK, N.A., MORGAN STANLEY SENIOR FUNDING, INC., MIZUHO BANK, LTD., and WELLS FARGO SECURITI |
|
| July 22, 2025 |
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 •Second quarter revenues of $2.76 billion, up 15.2% from 2024 •Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 •Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 •Fu |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 22, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-12215 A. Full title of the pla |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Jurisdiction |
|
| June 20, 2025 |
S-3ASR EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid 1 Debt Debt Securities Rule 456(b) and Rule 457(r) 0. |
|
| May 22, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 15, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 23, 2025 |
Form of Quest Diagnostics Incorporated 2025 Equity Award Agreement Equity Award Agreement Page | 1 Exhibit 10.1 Quest Diagnostics Incorporated 2025 Equity Award Agreement This Equity Award Agreement (the “Agreement”) dated as of #GrantDate# (the “Grant Date”) between Quest Diagnostics Incorporated, 500 Plaza Drive, Secaucus, NJ 07094 (the “Company”) and the employee to whom the awards described herein are made (the “Employee”) is subject in all respects to the Co |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| April 23, 2025 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of April 23, 2025, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| April 22, 2025 |
Exhibit 99.1 Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 •First quarter revenues of $2.65 billion, up 12.1% from 2024 •First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024 •Full year 2025 reported diluted EPS now expected |
|
| April 22, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 22, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [] |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [X |
|
| March 19, 2025 |
Investor Day 2025 Quest Diagnostics Investor Day 2025 Quest Diagnostics Driving Sustainable Growth, Delivering Long-term Value Jim Davis Chairman, CEO, and President Investor Day 2025 Quest Diagnostics Safe harbor disclosure The statements in this presentation which are not historical facts may be forward-looking statements. |
|
| March 19, 2025 |
Improving Quality, Experiences, and Productivity Cathy Doherty Executive Vice President, Regional Businesses Alex Louis Senior Vice President, Enterprise Operations Investor Day 2025 Quest Diagnostics 2 INVESTOR DAY 2025 Quest Diagnostics Safe harbor disclosure The statements in this presentation which are not historical facts may be forward-looking statements. |
|
| March 19, 2025 |
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day • Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR • Reaffirms guidance for full year 2025 SECAUCUS, N. |
|
| March 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 19, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| March 19, 2025 |
Karthik Kuppusamy, PhD Senior Vice President, Clinical Solutions Diagnostic Innovation as a Growth Driver Investor Day 2025 Quest Diagnostics 2 INVESTOR DAY 2025 Quest Diagnostics Safe harbor disclosure The statements in this presentation which are not historical facts may be forward-looking statements. |
|
| March 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 19, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| March 19, 2025 |
Sam Samad Executive Vice President and Chief Financial Officer Long-term Financial Outlook Investor Day 2025 Quest Diagnostics 2 INVESTOR DAY 2025 Quest Diagnostics Safe harbor disclosure The statements in this press release which are not historical facts may be forward-looking statements. |
|
| February 20, 2025 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of February 20, 2025, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| February 20, 2025 |
Exhibit 10.9 AMENDED AND RESTATED QUEST DIAGNOSTICS INCORPORATED EXECUTIVE OFFICER SEVERANCE PLAN 1. Purpose. The purpose of the Quest Diagnostics Incorporated Executive Officer Severance Plan (together with the attached schedules, appendices and exhibits, the “Plan”) is to secure the continued services of the executive officers of the Company and provide these executives with certain termination |
|
| February 20, 2025 |
Quest Diagnostics Incorporated Policy on Securities Trading 1 QUEST DIAGNOSTICS INCORPORATED POLICY ON SECURITIES TRADING (Amended as of December 31, 2024) The federal securities laws impose civil and criminal penalties on a company, its directors, officers and other employees or those receiving information from a company, its directors, officers and other employees who transact in that company’s securities while in possession of “material non-public information” (as discussed below). |
|
| February 20, 2025 |
EXECUTION VERSION Quest Amendment No. 9 to 6th A&R CSA AMENDMENT NO. 9 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 9 to Sixth Amended and Restated Credit and Security Agreement (this “Amendment”) is entered into as of August 8, 2024 (the “Effective Date”), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors a |
|
| February 20, 2025 |
Execution Version Quest Amendment No. 10 to 6th A&R CSA 279334595.v4 AMENDMENT NO. 10 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 10 to Sixth Amended and Restated Credit and Security Agreement (this “Amendment”) is entered into as of November 20, 2024 (the “Effective Date”), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together wi |
|
| February 20, 2025 |
Subsidiaries of Quest Diagnostics Incorporated Exhibit 21.1 Quest Diagnostics Incorporated (DE) (Incorporated on December 12, 1990 in Delaware; EIN: 16-1387862) Subsidiaries, Joint Ventures and Affiliates Company Registered Alternate name 100% Quest Diagnostics Holdings Incorporated (DE) 100% Quest Diagnostics International Holdings Limited (UK) 100% Quest Diagnostics Holdings Ltd. (UK) 100% ExamOne Canada, Inc. (New Brunswick) 99.9% Quest Dia |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| February 20, 2025 |
Exhibit 4.25 DESCRIPTION OF COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a description of the material terms of the common stock, par value $0.01 per share (“common stock”) of Quest Diagnostics Incorporated (the “Company”) included in our restated certificate of incorporation and our amended and restated by-laws and is only a summar |
|
| February 20, 2025 |
Second Amendment to Quest Diagnostics Supplemental Deferred Compensation Plan (Post - 2004) (amended and restated December 1, 2020) The Quest Diagnostics Supplemental Deferred Compensation Plan (Post-2004), as amended and restated December 1, 2020) is hereby amended in the following respects effective as stated herein: 1. |
|
| February 20, 2025 |
Amendment No. 1 to The Quest Diagnostics Profit Sharing Plan, dated as of December 9, 2024 AMENDMENT NO. 1 TO THE QUEST DIAGNOSTICS PROFIT SHARING PLAN (as amended and restated effective September 14, 2023) The Quest Diagnostics Profit Sharing Plan, as presently maintained under an amendment and restatement effective as of September 14, 2023 (the "Plan"), is hereby amended, effective as of January 1, 2025 (unless a different effective date is indicated), in the following respects: 1. Se |
|
| January 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 30, 2025 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| January 30, 2025 |
Exhibit 99.1 Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share •Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 •Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 •Full year r |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| October 23, 2024 |
Restated Certificate of Incorporation Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF QUEST DIAGNOSTICS INCORPORATED The present name of the corporation is Quest Diagnostics Incorporated. The corporation was incorporated under the name “Corning Lab Services Inc.” by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 12, 1990. This Restated Certificate of Incorp |
|
| October 23, 2024 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of October 23, 2024, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| October 22, 2024 |
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024 Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024 •Third quarter revenues of $2.49 billion, up 8.5% from 2023 •Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023 •Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion; r |
|
| October 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 22, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| August 29, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 23, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| August 29, 2024 |
Press Release of Quest Diagnostics Incorporated dated August 26, 2024 |
|
| August 19, 2024 |
Underwriting Agreement, dated August 15, 2024 Exhibit 1.1 Execution Version QUEST DIAGNOSTICS INCORPORATED (a Delaware corporation) $400,000,000 4.600% Senior Notes due 2027 $600,000,000 4.625% Senior Notes due 2029 $850,000,000 5.000% Senior Notes due 2034 UNDERWRITING AGREEMENT Dated: August 15, 2024 Table of Contents Page SECTION 1. Representations and Warranties 3 (a) Representations and Warranties by the Company 3 (b) Officer’s Certifica |
|
| August 19, 2024 |
Amended and Restated By-Laws of Quest Diagnostics Incorporated, as amended August 14, 2024 Exhibit 3.1 QUEST DIAGNOSTICS INCORPORATED AMENDED AND RESTATED BY-LAWS As amended through August 14, 2024 QUEST DIAGNOSTICS INCORPORATED a Delaware corporation AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 4 Section 1.01. Annual Meetings 4 Section 1.02. Special Meetings 4 Section 1.03. Notice of Meetings 6 Section 1.04. Quorum; Required Stockholder Vote 7 Section 1.05 |
|
| August 19, 2024 |
Quest Diagnostics Prices $1.85 Billion of Senior Notes Exhibit 99.1 Quest Diagnostics Prices $1.85 Billion of Senior Notes Secaucus, NJ – August 15, 2024 –Quest Diagnostics Incorporated (NYSE: DGX) (the “Company”), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the “2027 notes”), $600 million aggregate principal amount of its |
|
| August 19, 2024 |
Exhibit 4.2 QUEST DIAGNOSTICS INCORPORATED, as Issuer and THE BANK OF NEW YORK MELLON, as Trustee Twenty-Third Supplemental Indenture Dated as of August 19, 2024 TABLE OF CONTENTS Page Article I. DEFINITIONS 3 SECTION 1.1. Certain Terms Defined in the Indenture 3 SECTION 1.2. Definitions 3 SECTION 1.3. Other Definitions 6 Article II. FORM AND TERMS OF THE NOTES 6 SECTION 2.1. Form and Dating 6 SEC |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 14, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| August 16, 2024 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 QUEST DIAGNOSTICS INC Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt 4. |
|
| August 16, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-266315 PROSPECTUS SUPPLEMENT (To prospectus dated July 25, 2022) $1,850,000,000 Quest Diagnostics Incorporated $400,000,000 4.600% senior notes due 2027 $600,000,000 4.625% senior notes due 2029 $850,000,000 5.000% senior notes due 2034 We are offering $400,000,000 aggregate principal amount of 4.600% senior notes due 2027, |
|
| August 15, 2024 |
Free Writing Prospectus Filed pursuant to Rule 433 August 15, 2024 Registration Statement No. |
|
| August 15, 2024 |
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 24, 2024 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of July 24, 2024, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| July 24, 2024 |
EXECUTION VERSION 1381-5604-3275.29 EQUITY PURCHASE AGREEMENT by and among BOREALIS INFRASTRUCTURE CORPORATION, BPC HEALTH TRUST, LIFELABS INC., BPC LAB FINANCE LP, 1000923563 ONTARIO INC. and QUEST DIAGNOSTICS INCORPORATED Exhibit 10.1 * Certain information contained in this exhibit, marked by [***], has been omitted because it (i) is not material and (ii) is the type of information that we treat |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 23, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| July 23, 2024 |
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 •Second quarter revenues of $2.40 billion, up 2.5% from 2023 •Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2% from 2023 •Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billio |
|
| July 3, 2024 |
Quest Diagnostics to Acquire LifeLabs from OMERS, Enhancing Diagnostic Services for Canadians Exhibit 99.1 Quest Diagnostics to Acquire LifeLabs from OMERS, Enhancing Diagnostic Services for Canadians Secaucus, NJ and Toronto, Canada — July 3, 2024— Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians, for a value |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 2, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-12215 A. Full title of the pla |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 16, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 21, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF QUEST DIAGNOSTICS INCORPORATED Quest Diagnostics Incorporated, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: 1. The Restated Certificate of Incorporation of the Corporation is hereby amended by amending paragraph (a) of Paragraph 11 thereof to |
|
| May 21, 2024 |
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors Exhibit 99.1 Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors SECAUCUS, N.J. – May 16, 2024 – Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 16, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| April 24, 2024 |
Form of Quest Diagnostics Incorporated 2024 Equity Award Agreement Equity Award Agreement [Grant Date] EXHIBIT 10.1 Page | 1 Quest Diagnostics Incorporated 2024 Equity Award Agreement This Equity Award Agreement (the “Agreement”) dated as of [Grant Date] (the “Grant Date”) between Quest Diagnostics Incorporated, 500 Plaza Drive, Secaucus, NJ 07094 (the “Company”) and the employee to whom the awards described herein are made (the “Employee”) is subject in all resp |
|
| April 24, 2024 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of April 24, 2024, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| April 23, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 23, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 23, 2024 |
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 Exhibit 99.1 Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 •First quarter revenues of $2.37 billion, up 1.5% from 2023 •First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023 •Full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion; rep |
|
| April 11, 2024 |
Vote “Yes” on Shareholder Proposal #5 Quest Diagnostics (DGX) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 Quest shareholder since 2012 Please Support Item #5 for Managing Climate Risk Through Science-Based Targets and Transition Planning To Quest Diagnostics Shareholders: I ask shareholders to vote FOR Item 5 at the Quest Diagnostics shareholder meeting on May 16, 2024. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [] |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [X |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [X] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [ |
|
| February 22, 2024 |
Subsidiaries of Quest Diagnostics Incorporated Exhibit 21.1 Quest Diagnostics Incorporated (DE) (Incorporated on December 12, 1990 in Delaware; EIN: 16-1387862) Subsidiaries, Joint Ventures and Affiliates Company Registered Alternate name 100% Quest Diagnostics Holdings Incorporated (DE) 100% Quest Diagnostics International Holdings Limited (UK) 100% Quest Diagnostics Holdings Ltd. (UK) 100% ExamOne Canada, Inc. (New Brunswick) 99.9% Quest Dia |
|
| February 22, 2024 |
Quest Diagnostics Incorporated Dodd-Frank Clawback Policy, adopted November 13, 2023 Exhibit 97.1 QUEST DIAGNOSTICS INCORPORATED DODD-FRANK CLAWBACK POLICY The Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”) has adopted this Dodd-Frank Clawback Policy (this “Policy”) in accordance with the applicable provisions of The New York Stock Exchange Listed Company Manual (the “Clawback Rules”), promulgated pursuant to the final rules adopted by the Secur |
|
| February 22, 2024 |
The Quest Diagnostics Profit Sharing Plan (Amendment and Restatement, effective as of Exhibit 10.9 THE QUEST DIAGNOSTICS PROFIT SHARING PLAN (Amendment and Restatement Effective as of September 14, 2023) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 3 ARTICLE II ELIGIBILITY AND PARTICIPATION 18 2.1. Eligibility 18 2.2. Participation 18 2.3. Beneficiary Designation 19 ARTICLE III CONTRIBUTIONS 21 3.1. Employee Contributions 21 3.2. Employer Matching Contributions 25 3.3. Employer Dis |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| February 22, 2024 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of February 22, 2024, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| February 13, 2024 |
DGX / Quest Diagnostics Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01773-questdiagnosticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Quest Diagnostics Inc Title of Class of Securities: Common Stock CUSIP Number: 74834L100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to d |
|
| February 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 1, 2024 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 1, 2024 |
Exhibit 99.1 Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share •Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 •Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6% from 2022 •Fourth qua |
|
| January 25, 2024 |
DGX / Quest Diagnostics Incorporated / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING QUEST DIAGNOSTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 74834L100 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FIL |
|
| January 24, 2024 |
DGX / Quest Diagnostics Incorporated / BlackRock Inc. Passive Investment SC 13G/A 1 us74834l1008012424.txt us74834l1008012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 15) QUEST DIAGNOSTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74834L100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 1, 2023 |
Exhibit 4.2 QUEST DIAGNOSTICS INCORPORATED, as Issuer and THE BANK OF NEW YORK MELLON, as Trustee Twenty-Second Supplemental Indenture Dated as of November 1, 2023 TABLE OF CONTENTS Page Article I. DEFINITIONS.................................................................................................................3 SECTION 1.1. Certain Terms Defined in the Indenture......................... |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 30, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| November 1, 2023 |
Exhibit 1.1 EXECUTION VERSION QUEST DIAGNOSTICS INCORPORATED (a Delaware corporation) $750,000,000 6.400% Senior Notes due 2033 UNDERWRITING AGREEMENT Dated: October 30, 2023 Table of Contents Page SECTION 1. Representations and Warranties 3 (a) Representations and Warranties by the Company 3 (b) Officer’s Certificates 14 SECTION 2. Sale and Delivery to Underwriters; Closing 14 (a) Notes 14 (b) Pu |
|
| November 1, 2023 |
Quest Diagnostics Prices $750 Million of Senior Notes Exhibit 99.1 Quest Diagnostics Prices $750 Million of Senior Notes SECAUCUS, N.J., October 30, 2023 /PRNewswire/ - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $750 million aggregate principal amount of its 6.400% senior notes due 2033 under Quest Diagnostics' shelf registration stat |
|
| October 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (1) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt 6. |
|
| October 31, 2023 |
$750,000,000 Quest Diagnostics Incorporated $750,000,000 6.400% Senior Notes due 2033 Filed Pursuant to Rule 424(b)(2) Registration No. 333-266315 PROSPECTUS SUPPLEMENT (To prospectus dated July 25, 2022) $750,000,000 Quest Diagnostics Incorporated $750,000,000 6.400% Senior Notes due 2033 We are offering $750,000,000 aggregate principal amount of 6.400% senior notes due 2033 (the “notes”). The notes will mature on November 30, 2033. We will pay interest on the notes semiannually o |
|
| October 30, 2023 |
Free Writing Prospectus Filed pursuant to Rule 433 October 30, 2023 Registration Statement No. |
|
| October 30, 2023 |
Subject to Completion Preliminary Prospectus Supplement, dated October 30, 2023 Filed Pursuant to Rule 424(b)(2) Registration No. 333-266315 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to |
|
| October 27, 2023 |
Registration No. ===================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ======================= FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ======================= QUEST DIAGNOSTICS INCORPORATED (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of i |
|
| October 27, 2023 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, Par Value $0. |
|
| October 25, 2023 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of October 25, 2023, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| October 25, 2023 |
Exhibit 99.1 AMENDMENT NO. 8 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 8 to Sixth Amended and Restated Credit and Security Agreement (this “Amendment”) is entered into as of October 19, 2023 (the “Effective Date”), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors and permitted assigns, the “Borrower”), ( |
|
| October 25, 2023 |
Exhibit 99.2 AMENDMENT NO. 2 TO FOURTH AMENDED AND RESTATED RECEIVABLES SALE AGREEMENT THIS AMENDMENT NO. 2 TO FOURTH AMENDED AND RESTATED RECEIVABLES SALE AGREEMENT (as amended, supplemented, restated or otherwise modified from time to time, this “Amendment”), dated as of October 19, 2023, is entered into by and between: (1) Quest Diagnostics Incorporated, a Delaware corporation, Quest Diagnostic |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 24, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| October 24, 2023 |
Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 •Third quarter revenues of $2.30 billion, down 7.7% from 2022 •Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9% from 2022 •Third quarter base business revenues of $2.27 billion, up 4.6% from 2022 •Full |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 28, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| July 27, 2023 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of July 27, 2023, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| July 27, 2023 |
Exhibit 10.2 Amended and Restated Employee Stock Purchase Plan (As approved by the stockholders on May 4, 2006 and as amended effective as of May 16, 2023) The purpose of the Employee Stock Purchase Plan (the “Program”) of Quest Diagnostics Incorporated (the “Corporation”) is to provide to employees an ongoing opportunity to purchase shares of Common Stock of the Corporation, par value $0.01 per s |
|
| July 27, 2023 |
Exhibit 10.1 Amended and Restated Quest Diagnostics Incorporated Employee Long-Term Incentive Plan (As amended March 31, 2023) 1. THE PLAN (a) Purpose. This Amended and Restated Quest Diagnostics Incorporated Employee Long-Term Incentive Plan (the “Plan”) is intended to benefit the stockholders of Quest Diagnostics Incorporated (the “Company”) by providing a means to attract, retain and reward ind |
|
| July 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 26, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| July 26, 2023 |
Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 •Second quarter revenues of $2.34 billion, down 4.7% from 2022 •Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5% from 2022 •Second quarter base business revenues of $2.30 billion, up 9.5% from 2022 •Ful |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-12215 A. Full title of the pla |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 17, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 28, 2023 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of April 28, 2023, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| April 28, 2023 |
Exhibit 99.1 THIRD AMENDED AND RESTATED CREDIT AGREEMENT Dated as of November 23, 2021 among QUEST DIAGNOSTICS INCORPORATED, as Borrower, THE LENDERS IDENTIFIED HEREIN, JPMORGAN CHASE BANK, N.A., as Administrative Agent, and MORGAN STANLEY SENIOR FUNDING, INC., as Syndication Agent JPMORGAN CHASE BANK, N.A., MORGAN STANLEY SENIOR FUNDING, INC., MIZUHO BANK, LTD., and WELLS FARGO SECURITIES, LLC, a |
|
| April 27, 2023 |
Exhibit 99.2 Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack’s highly sensitive minimal-residual disease cancer-detection technology to be combined with Quest’s oncology, genomics and patho |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 27, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 27, 2023 |
Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 Exhibit 99.1 Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 •First quarter revenues of $2.33 billion, down 10.7% from 2022 •First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down 36.6% from 2022 •First quarter base business revenues of $2.21 billion, up 10.0% from 2022 •F |
|
| April 10, 2023 |
Quest Diagnostics (DGX) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 Quest shareholder since 2012 Please Support Item #6 for Greenhouse Gas Reduction and Transition Plan To Quest Diagnostics Shareholders: I ask shareholders to vote FOR Item 6 at the Quest Diagnostics shareholder meeting on May 17, 2023. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [X |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [] |
|
| March 17, 2023 |
2023 INVESTOR DAY Molecular Genomics and Oncology Mark Gardner Senior Vice President, Molecular Genomics & Oncology The statements in the following presentations which are not historical facts may be forward looking statements. |
|
| March 17, 2023 |
2023 INVESTOR DAY Long Term Financial Outlook Sam Samad Executive Vice President, Chief Financial Officer SAFE HARBOR DISCLOSURE The statements in the following presentations which are not historical facts may be forward looking statements. |
|
| March 17, 2023 |
2023 INVESTOR DAY Driving Sustainable Growth in a Post-Pandemic World Jim Davis Chief Executive Officer and President SAFE HARBOR DISCLOSURE The statements in the following presentations which are not historical facts may be forward looking statements. |
|
| March 17, 2023 |
2023 INVESTOR DAY Optimizing Operations to Drive Growth Cathy Doherty Senior Vice President, Regional Businesses SAFE HARBOR DISCLOSURE The statements in the following presentations which are not historical facts may be forward looking statements. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 16, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| March 17, 2023 |
Quest Diagnostics to Discuss Strategic Priorities to Drive Growth and Create Shareholder Value at 2023 Investor Day • Updates 2023-26 compound annual growth rate (CAGR): Revenues expected to grow at mid single-digit rate; adjusted diluted earnings per share (EPS)* expected to grow at high single-digit rate • Recommits to Invigorate savings and productivity improvements of approximately 3% annually • Guidance for 2023 provided on February 2, 2023 remains unchanged SECAUCUS, N. |
|
| March 7, 2023 |
Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board Exhibit 99.1 Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board SECAUCUS, N.J., DATE /PRNewswire/ - Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of th |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 3, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 21, 2023 |
Exhibit 10.5 Amendment No. 1 to Quest Diagnostics Supplemental Deferred Compensation Plan (as amended and restated December 1, 2020) The Quest Diagnostics Supplemental Deferred Compensation Plan (Post — 2004), as amended and restated December 1, 2020, is hereby amended effective November 29, 2022, by amending and restating Section 3.2(a) to provide: (a) Employer Contributions. An Employer shall cr |
|
| February 21, 2023 |
Exhibit 99.10 AMENDMENT NO. 7 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 7 to Sixth Amended and Restated Credit and Security Agreement (this “Amendment”) is entered into as of October 20, 2022 (the “Effective Date”), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors and permitted assigns, the “Borrower”), |
|
| February 21, 2023 |
Exhibit 99.12 GROUP JOINDER AGREEMENT Dated as of August 13, 2021 THIS GROUP JOINDER AGREEMENT (this “Joinder Agreement”) is executed and delivered by Reprosource Fertility Diagnostics, Inc., a Massachusetts corporation, Blueprint Genetics, Inc., a Delaware corporation, and Mid America Clinical Laboratories, LLC, an Indiana limited liability company (each, a “New Seller” and collectively, the “New |
|
| February 21, 2023 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of February 21, 2023, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| February 21, 2023 |
Exhibit 4.32 DESCRIPTION OF COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a description of the material terms of the common stock, par value $0.01 per share (“common stock”) of Quest Diagnostics Incorporated (the “Company”) included in our restated certificate of incorporation and our amended and restated by-laws and is only a summar |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| February 21, 2023 |
Subsidiaries of Quest Diagnostics Incorporated Exhibit 21.1 Quest Diagnostics Incorporated (DE) (Incorporated on December 12, 1990 in Delaware; EIN: 16-1387862) Subsidiaries, Joint Ventures and Affiliates Company Registered Alternate name 100% Quest Diagnostics Holdings Incorporated (DE) 100% Quest Diagnostics International Holdings Limited (UK) 100% Quest Diagnostics Holdings Ltd. (UK) 100% ExamOne Canada, Inc. (New Brunswick) 99.9% Quest Dia |
|
| February 21, 2023 |
Exhibit 10.10 AMENDMENT NO. 1 TO THE QUEST DIAGNOSTICS PROFIT SHARING PLAN (as amended and restated effective August 15, 2021) The Quest Diagnostics Profit Sharing Plan, as presently maintained under an amendment and restatement effective August 15, 2021 (the “Plan”), is hereby amended in the following respects, effective as provided: 1.Effective January 1, 2022, the first paragraph of the definit |
|
| February 21, 2023 |
Exhibit 10.20 AIRCRAFT TIME SHARING AGREEMENT Dated as of the 16th day of February, 2023, between QUEST DIAGNOSTICS CLINICAL LABORATORIES, INC., as Time Share Lessor, and JAMES E. DAVIS, as Time Share Lessee, concerning the aircraft listed in Exhibit B hereto * * * INSTRUCTIONS FOR COMPLIANCE WITH "TRUTH IN LEASING" REQUIREMENTS UNDER FAR § 91.23 Within 24 hours after execution of this Agreement: |
|
| February 9, 2023 |
DGX / Quest Diagnostics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Quest Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 74834L100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 7, 2023 |
DGX / Quest Diagnostics Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING QUEST DIAGNOSTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 74834L100 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS |
|
| February 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 2, 2023 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 2, 2023 |
Exhibit 99.1 QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023 •Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 •Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down 40.5% from 2021 •Fourth quarter base business revenues of $2.15 billion, up |
|
| February 2, 2023 |
Exhibit 99.2 Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization SECAUCUS, N.J., Feb. 2, 2023 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the Company’s Board of Directors has authorized a 7.6% increase in its quarterly dividend from $0.66 to |
|
| January 23, 2023 |
DGX / Quest Diagnostics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us74834l1008012323.txt us74834l1008012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) QUEST DIAGNOSTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74834L100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| November 18, 2022 |
Exhibit 3.1 QUEST DIAGNOSTICS INCORPORATED AMENDED AND RESTATED BY-LAWS As amended through November 14, 2022 QUEST DIAGNOSTICS INCORPORATED a Delaware corporation AMENDED AND RESTATED BY-LAWS 2 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS ......................................................................................................4 Section 1.01. Annual Meetings .......................... |
|
| November 18, 2022 |
Exhibit 10.1 AMENDED AND RESTATED QUEST DIAGNOSTICS INCORPORATED EXECUTIVE OFFICER SEVERANCE PLAN 1. Purpose. The purpose of the Quest Diagnostics Incorporated Executive Officer Severance Plan (together with the attached schedules, appendices and exhibits, the ?Plan?) is to secure the continued services of the executive officers of the Company and provide these executives with certain termination |
|
| November 1, 2022 |
Exhibit 99.1 Quest Diagnostics Completes Leadership Succession as Jim Davis Becomes CEO and President, Joins Board of Directors ?Former CEO Steve Rusckowski remains as Chairman through March 2023 Secaucus, NJ, Nov. 1, 2022 ? Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Jim Davis has succeeded Steve Rusckowski as the CEO and Pr |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 31, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| October 28, 2022 |
EX-10.1 2 dgx10282022ex101.htm EX-10.1 EXHIBIT 10.1 AMENDED AND RESTATED QUEST DIAGNOSTICS INCORPORATED EXECUTIVE OFFICER SEVERANCE PLAN 1. Purpose. The purpose of the Quest Diagnostics Incorporated Executive Officer Severance Plan (together with the attached schedules, appendices and exhibits, the “Plan”) is to secure the continued services of the executive officers of the Company and provide the |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 28, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| October 21, 2022 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of October 21, 2022, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| October 21, 2022 |
EXHIBIT 10.1 AMENDED AND RESTATED QUEST DIAGNOSTICS INCORPORATED EXECUTIVE OFFICER SEVERANCE PLAN 1. Purpose. The purpose of the Quest Diagnostics Incorporated Executive Officer Severance Plan (together with the attached schedules, appendices and exhibits, the ?Plan?) is to secure the continued services of the executive officers of the Company and provide these executives with certain termination |
|
| October 21, 2022 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF QUEST DIAGNOSTICS INCORPORATED The present name of the corporation is Quest Diagnostics Incorporated. The corporation was incorporated under the name ?Corning Lab Services Inc.? by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 12, 1990. This Restated Certificate of Incorp |
|
| October 20, 2022 |
Quest Diagnostics Reports Third Quarter 2022 Financial Results; Raises Guidance for Full Year 2022 Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2022 Financial Results; Raises Guidance for Full Year 2022 ?Third quarter revenues of $2.49 billion, down 10.4% from 2021 ?Third quarter reported diluted earnings per share ("EPS") of $2.17, down 46.0% from 2021; and adjusted diluted EPS of $2.36, down 40.4% from 2021 ?Third quarter base business revenues of $2.17 billion, up 5.1% from 2021 ?Ful |
|
| October 20, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 20, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| July 25, 2022 |
Exhibit 22.1 Subsidiary Guarantors of Securities As of July 25, 2022, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities |
|
| July 25, 2022 |
As filed with the Securities and Exchange Commission on July 25, 2022 As filed with the Securities and Exchange Commission on July 25, 2022 Registration No. |
|
| July 25, 2022 |
EX-25.1 5 ss1185741ex2501.htm STATEMENT OF ELIGIBILITY Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON (Exact name of trus |
|
| July 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrat |
|
| July 22, 2022 |
Exhibit 22 Subsidiary Guarantors of Securities As of July 22, 2022, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| July 21, 2022 |
Quest Diagnostics Reports Second Quarter 2022 Financial Results; Raises Guidance for Full Year 2022 Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2022 Financial Results; Raises Guidance for Full Year 2022 ?Second quarter revenues of $2.45 billion, down 3.8% from 2021 ?Second quarter reported diluted earnings per share ("EPS") of $1.96, down 60.5% from 2021; and adjusted diluted EPS of $2.36, down 25.8% from 2021 ?Second quarter base business revenues of $2.10 billion, up 2.9% from 2021 ? |
|
| July 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 21, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No. |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) 11-K 1 dgx12312021profitsharingpl.htm 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| June 14, 2022 |
Quest Diagnostics Names Sam Samad Executive Vice President and Chief Financial Officer Exhibit 99.1 Quest Diagnostics Names Sam Samad Executive Vice President and Chief Financial Officer SECAUCUS, N.J., June 9, 2022 - Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sam Samad will become Executive Vice President and Chief Financial Officer. He will succeed Mark Guinan, who, in February, following eight and a half ye |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 8, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 20, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 18, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 19, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| May 20, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF QUEST DIAGNOSTICS INCORPORATED Quest Diagnostics Incorporated, a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies that: 1. The Restated Certificate of Incorporation of the Corporation is hereby amended by amending Paragraph 7 to read in its entirety as fo |
|
| May 20, 2022 |
Amended and Restated By-laws of Quest Diagnostics Incorporated, as amended effective May 19, 2022 Exhibit 3.2 QUEST DIAGNOSTICS INCORPORATED AMENDED AND RESTATED BY-LAWS As amended through May 19, 2022 QUEST DIAGNOSTICS INCORPORATED a Delaware corporation AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 4 Section 1.01. Annual Meetings 4 Section 1.02. Special Meetings 4 Section 1.03. Notice of Meetings 6 Section 1.04. Quorum; Required Stockholder Vote 7 Section 1.05. N |
|
| April 22, 2022 |
Quest Diagnostics Incorporated (DGX) Quest Diagnostics Incorporated (DGX) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 Quest Diagnostics Shareholder since 2012 Please Vote For Proposal 6 ? Shareholder Right to Call a Special Shareholder Meeting It is important to vote for this Proposal to address the major league strike against our current right to call a special shareholder meeting. |
|
| April 22, 2022 |
Exhibit 22 Subsidiary Guarantors of Securities As of April 22, 2022, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| April 21, 2022 |
Quest Diagnostics Reports First Quarter 2022 Financial Results; Raises Guidance for Full Year 2022 Exhibit 99.1 Quest Diagnostics Reports First Quarter 2022 Financial Results; Raises Guidance for Full Year 2022 ?First quarter revenues of $2.61 billion, down 4.0% from 2021 ?First quarter reported diluted earnings per share ("EPS") of $2.92, down 15.6% from 2021; and adjusted diluted EPS of $3.22, down 14.4% from 2021 ?Base business revenues of $2.01 billion, up 6.3% from 2021 ?Full year 2022 rep |
|
| April 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 21, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| April 19, 2022 |
DEF 14A 1 ss916215def14a.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF |
|
| April 8, 2022 |
DGX / Quest Diagnostics Inc / BlackRock Inc. Passive Investment us74834l1008040722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 13) QUEST DIAGNOSTICS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 74834L100 - (CUSIP Number) March 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| April 5, 2022 |
PRE 14A 1 ss907775pre14a.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [X] Preliminary Proxy Statement [] CONFIDENTIAL, FOR USE OF |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 24, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 24, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 28, 2022 |
Subsidiary Guarantors of Securities Exhibit 22 Subsidiary Guarantors of Securities As of February 1, 2022, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| February 28, 2022 |
Exhibit 99.9 AMENDMENT NO. 6 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 6 to Sixth Amended and Restated Credit and Security Agreement (this ?Amendment?) is entered into as of October 21, 2021 (the ?Effective Date?), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors and permitted assigns, the ?Borrower?), ( |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| February 28, 2022 |
Subsidiaries of Quest Diagnostics Incorporated Exhibit 21.1 Quest Diagnostics Incorporated (DE) (Incorporated on December 12, 1990 in Delaware; EIN: 16-1387862) Subsidiaries, Joint Ventures and Affiliates as of February 1, 2022 Company Registered Alternate name 100% Quest Diagnostics Holdings Incorporated (DE) 100% Quest Diagnostics International Holdings Limited (UK) 100% Quest Diagnostics Holdings Ltd. (UK) 100% ExamOne Canada, Inc. (New Bru |
|
| February 28, 2022 |
Exhibit 99.10 THIRD AMENDED AND RESTATED CREDIT AGREEMENT Dated as of November 23, 2021 among QUEST DIAGNOSTICS INCORPORATED, as Borrower, THE LENDERS IDENTIFIED HEREIN, JPMORGAN CHASE BANK, N.A., as Administrative Agent, and MORGAN STANLEY SENIOR FUNDING, INC., as Syndication Agent JPMORGAN CHASE BANK, N.A., MORGAN STANLEY SENIOR FUNDING, INC., MIZUHO BANK, LTD., and WELLS FARGO SECURITIES, LLC, |
|
| February 10, 2022 |
DGX / Quest Diagnostics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Quest Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 74834L100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 10, 2022 |
DGX / Quest Diagnostics Inc / STATE STREET CORP Passive Investment SC 13G 1 QUESTDIAGNOSTICSINC.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING QUEST DIAGNOSTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 74834L100 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PU |
|
| February 7, 2022 |
DGX / Quest Diagnostics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us74834l1008020722.txt us74834l1008020722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) QUEST DIAGNOSTICS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 74834L100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 3, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 3, 2022 |
Quest Diagnostics Announces Leadership Succession Plan Quest Diagnostics Announces Leadership Succession Plan - Chairman and CEO Steve Rusckowski to remain CEO through October 2022 and continue as Executive Chairman - James E. |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 3, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| February 3, 2022 |
Exhibit 99.1 QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2022; INCREASES QUARTERLY DIVIDEND 6.5% TO $0.66 PER SHARE ?Full year revenues of $10.79 billion, up 14.3% from 2020 ?Full year diluted earnings per share ("EPS") of $15.55, up 48.5% from 2020; and adjusted diluted EPS of $14.24, up 27.4% from 2020 ?Full year cash provided by |
|
| January 12, 2022 |
QUEST DIAGNOSTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS QUEST DIAGNOSTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS SECAUCUS, N. |
|
| January 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 12, 2022 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| October 22, 2021 |
Exhibit 99.1 AMENDMENT NO. 5 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This Amendment No. 5 to Sixth Amended and Restated Credit and Security Agreement (this ?Amendment?) is entered into as of August 13, 2021 (the ?Effective Date?), by and among: (1) QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors and permitted assigns, the ?Borrower?), (2 |
|
| October 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 (State of Incorporation) (I. |
|
| October 22, 2021 |
Exhibit 10.2 QUEST DIAGNOSTICS SUPPLEMENTAL DEFERRED COMPENSATION PLAN (POST ? 2004) AMENDED AND RESTATED DECEMBER 1, 2020 PREAMBLE Effective as of January 1, 1999, Quest Diagnostics adopted the Quest Diagnostics Supplemental Deferred Compensation Plan for the benefit of certain of its Employees. As a result of the enactment in 2004 of Section 409A of the Internal Revenue Code of 1986, as amended, |
|
| October 22, 2021 |
Exhibit 22 Subsidiary Guarantors of Securities As of October 22, 2021, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended: Securities Issuer Subsidiary Guarantor State of Organization 6. |
|
| October 22, 2021 |
Exhibit 10.1 THE QUEST DIAGNOSTICS PROFIT SHARING PLAN (Amendment and Restatement, Effective as of August 15, 2021) 141815.2 Table of Contents Page ARTICLE I DEFINITIONS 3 ARTICLE II ELIGIBILITY AND PARTICIPATION 18 2.1. Eligibility 18 2.2. Participation 18 2.3. Beneficiary Designation 19 ARTICLE III CONTRIBUTIONS 21 3.1. Employee Pre-Tax Contributions 21 3.2. Employer Matching Contributions 25 3. |
|
| October 21, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 21, 2021 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| October 21, 2021 |
Quest Diagnostics Reports Third Quarter 2021 Financial Results, Raises Outlook for Full Year 2021 EX-99.1 2 dgx093020218-kex991.htm EX-99.1 Quest Diagnostics Reports Third Quarter 2021 Financial Results, Raises Outlook for Full Year 2021 •Third quarter revenues of $2.77 billion, down 0.4% from 2020 •Third quarter reported diluted earnings per share ("EPS") of $4.02, down 2.8% from 2020; and adjusted diluted EPS of $3.96, down 7.9% from 2020 •Year to date cash provided by operations of $1.75 bi |
|
| October 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 8, 2021 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| September 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 9, 2021 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| September 9, 2021 |
QUEST DIAGNOSTICS UPDATES OUTLOOK FOR FULL YEAR 2021 QUEST DIAGNOSTICS UPDATES OUTLOOK FOR FULL YEAR 2021 ?Revenues for full year 2021 now expected to be $9. |
|
| August 19, 2021 |
Quest Diagnostics Elects Tracey C. Doi to Board of Directors EX 99.1 Quest Diagnostics Elects Tracey C. Doi to Board of Directors SECAUCUS, N.J., August 17, 2021 /PRNewswire/ - Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Ms. Tracey C. Doi to serve as a director. Including Ms. Doi, the company's Board has 10 members. Ms. Doi is the Chief Financial Offi |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 16, 2021 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 16, 2021 Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I. |
|
| August 17, 2021 |
Quest Diagnostics Elects Tracey C. Doi to Board of Directors EX 99.1 Quest Diagnostics Elects Tracey C. Doi to Board of Directors SECAUCUS, N.J., August 17, 2021 /PRNewswire/ - Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Ms. Tracey C. Doi to serve as a director. Including Ms. Doi, the company's Board has 10 members. Ms. Doi is the Chief Financial Offi |
